Terms: = Colorectal cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
23 results:
1. Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
Kuol N; Godlewski J; Kmiec Z; Vogrin S; Fraser S; Apostolopoulos V; Nurgali K
BMC Cancer; 2023 Oct; 23(1):971. PubMed ID: 37828429
[TBL] [Abstract] [Full Text] [Related]
2. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of colorectal cancer.
Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056
[TBL] [Abstract] [Full Text] [Related]
3. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.
Babar Q; Saeed A; Murugappan S; Dhumal D; Tabish T; Thorat ND
Drug Discov Today; 2023 Jun; 28(6):103577. PubMed ID: 37004983
[TBL] [Abstract] [Full Text] [Related]
4. PD-L1 and PD-L2 expression in colorectal cancer.
Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
[TBL] [Abstract] [Full Text] [Related]
5. Pucotenlimab: First Approval.
Dhillon S
Drugs; 2022 Oct; 82(15):1557-1564. PubMed ID: 36308601
[TBL] [Abstract] [Full Text] [Related]
6. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract] [Full Text] [Related]
7. colorectal cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
Front Immunol; 2021; 12():778329. PubMed ID: 34975867
[TBL] [Abstract] [Full Text] [Related]
8. Quantification of adipose tissues by Dual-Energy X-Ray Absorptiometry and Computed Tomography in colorectal cancer patients.
Alavi DH; Henriksen HB; Lauritzen PM; Kværner AS; Sakinis T; Langleite TM; Henriksen C; Bøhn SK; Paur I; Wiedswang G; Smeland S; Blomhoff R
Clin Nutr ESPEN; 2021 Jun; 43():360-368. PubMed ID: 34024541
[TBL] [Abstract] [Full Text] [Related]
9. DSCMF: prediction of LncRNA-disease associations based on dual sparse collaborative matrix factorization.
Liu JX; Gao MM; Cui Z; Gao YL; Li F
BMC Bioinformatics; 2021 May; 22(Suppl 3):241. PubMed ID: 33980147
[TBL] [Abstract] [Full Text] [Related]
10. Advanced breast cancer with cachexia: A case report.
Liu N; Li S; Jia J; Qiao Y; Li Y
Medicine (Baltimore); 2021 Jan; 100(4):e24397. PubMed ID: 33530236
[TBL] [Abstract] [Full Text] [Related]
11. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
[TBL] [Abstract] [Full Text] [Related]
12. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract] [Full Text] [Related]
13. The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
Shrestha S; Olén O; Eriksson C; Everhov ÅH; Myrelid P; Visuri I; Ludvigsson JF; Schoultz I; Montgomery S; Sachs MC; Halfvarson J; ; Olsson M; Hjortswang H; Bengtsson J; Strid H; Andersson M; Jäghult S; Eberhardson M; Nordenvall C; Björk J; Fagerberg UL; Rejler M; Grip O; Karling P; Block M; Angenete E; Hellström PM; Gustavsson A
Scand J Gastroenterol; 2020 Apr; 55(4):430-435. PubMed ID: 32370571
[No Abstract] [Full Text] [Related]
14. Designing of novel zinc(ii) Schiff base complexes having acyl hydrazone linkage: study of phosphatase and anti-cancer activities.
Dasgupta S; Karim S; Banerjee S; Saha M; Das Saha K; Das D
Dalton Trans; 2020 Jan; 49(4):1232-1240. PubMed ID: 31903474
[TBL] [Abstract] [Full Text] [Related]
15. In vitro nephrotoxicity and anticancer potency of newly synthesized cadmium complexes.
Abyar S; Khandar AA; Salehi R; Abolfazl Hosseini-Yazdi S; Alizadeh E; Mahkam M; Jamalpoor A; White JM; Shojaei M; Aizpurua-Olaizola O; Masereeuw R; Janssen MJ
Sci Rep; 2019 Oct; 9(1):14686. PubMed ID: 31604983
[TBL] [Abstract] [Full Text] [Related]
16. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic colorectal cancer.
Floudas CS; Brar G; Mabry-Hrones D; Duffy AG; Wood B; Levy E; Krishnasamy V; Fioravanti S; Bonilla CM; Walker M; Morelli MP; Kleiner DE; Steinberg SM; Figg WD; Greten TF; Xie C
Clin Colorectal Cancer; 2019 Dec; 18(4):e349-e360. PubMed ID: 31351862
[TBL] [Abstract] [Full Text] [Related]
17. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
[TBL] [Abstract] [Full Text] [Related]
18. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
[TBL] [Abstract] [Full Text] [Related]
19. [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
Dreyer C; Afchain P; Trouilloud I; André T
Bull Cancer; 2016; 103(7-8):643-50. PubMed ID: 27345450
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of colon tumor growth by IL-15 immunogene therapy.
He X; Li W; Wang Y; Hou L; Zhu L
Mol Med Rep; 2012 Jan; 5(1):96-102. PubMed ID: 21956355
[TBL] [Abstract] [Full Text] [Related]
[Next]
